Fresenius Signs Record Biosimilars Development Deal With WuXi Biologics for Up to 37 Candidates

Fresenius SE & Co. KGaA has secured option rights to as many as 37 biosimilar candidates under an exclusive development agreement with China's WuXi Biologics, a transaction the German healthcare group called the largest development agreement announced in the biosimilars industry to date. The deal, announced on 2 November 2026, gives Fresenius access to a set of identified molecules over the next decade and marks one of the most ambitious pipeline expansions attempted by a European pharmaceutical company.

Reuters reported on 2 November 2026 that the agreement gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade, and that those candidates address more than €370 billion ($414 billion) in originator sales. The company currently has 29 marketed and pipeline molecules. If all options are exercised, the portfolio could reach as many as 66 products by the next decade, more than doubling the current total.

The financial scale explains the attention. Fresenius frames the opportunity in terms of originator sales: the 37 candidates together address more than €370 billion in list price based revenue from the original branded products. That figure explains why the company is willing to commit to a decade long development programme and why the agreement is being watched across the industry. It also explains why Fresenius is linking the deal to ambitions that extend beyond its previously announced 2030 targets.

Fresenius already markets and develops biosimilars through its Biopharma business and the mAbxience network. The company reported €22.6 billion in revenue for 2025 and employs more than 178,000 people in over 60 countries. It reports third quarter results on 4 November 2026. Reuters reported on 2 November 2026 that Fresenius confirmed its financial targets for 2026 and the medium term but expected to raise long term Biopharma ambitions significantly.

Key Facts

The headline numbers are unusually large for a biosimilars partnership. Fresenius said the option rights cover up to 37 potential first to market biosimilar candidates, taking the portfolio from 29 marketed and pipeline molecules to as many as 66 in the next decade. The candidates address more than €370 billion in originator list price based sales, according to the company. Fierce Pharma reported on 2 November 2026 that the combined originator market was worth over €370 billion.

Contract Pharma reported on 2 November 2026 that Fresenius described the arrangement as the largest biosimilars development agreement in the industry's history and said it could more than double the company's biosimilars portfolio over the next decade. The report said Fresenius will retain exclusive global commercialization rights and full economic ownership of products brought to market, with programmes selected individually on commercial potential, development risk and expected returns.

The pipeline is expected to span 13 therapeutic areas. Fresenius said it will broaden into neurology, nephrology and cardiopulmonary while strengthening oncology, immunology and gastroenterology. The candidate set includes monoclonal and bispecific antibodies, antibody drug conjugates and fusion proteins. That range matters because it moves the company beyond a narrow set of follow on products and into more complex biologic formats.

Initial development is expected to focus on polatuzumab vedotin, an antibody drug conjugate marketed by Genentech and Roche as Polivy for diffuse large B cell lymphoma, and teprotumumab, a monoclonal antibody marketed by Amgen as Tepezza for thyroid eye disease. Fierce Pharma reported on 2 November 2026 that the partnership will start with these two products and described both as blockbusters on a growing trajectory.

WuXi Biologics is characterized by Reuters as a leading global contract research, development and manufacturing organisation. Under the agreement, Fresenius is buying access to WuXi development capabilities rather than acquiring assets outright. Manufacturing will be decided on a candidate by candidate basis, with the option to use the mAbxience network, which Fresenius wholly owns after buying the remaining 45 percent stake in October 2026. Fresenius did not disclose other financial terms.

Analysis

What this really means is that Fresenius has found a way to add a large, long dated pipeline without paying the usual upfront price for it. Fierce Pharma reported on 2 November 2026 that Jefferies analysts read the fee for service structure as carrying no upfront or milestone payments. That is a meaningful judgement about risk allocation: Fresenius pays as programmes advance, so spending scales with progress rather than with the size of the option package. The company gets optionality, and WuXi gets a stream of service revenue tied to Fresenius selections.

The bigger picture here is that biosimilars have become a scale race. Fresenius is competing with Sandoz, whose Bio100 initiative targets more than 100 biosimilars by 2040 from 13 currently marketed products, and with Teva, which expanded its Samsung Bioepis collaboration to cover up to six additional programmes. Sandoz licensed three biosimilars from China's Henlius in August 2026 with options on seven more. Fierce Pharma reported on 2 November 2026 that Fresenius's nine marketed products represent about €85 billion in originator sales, according to Jefferies.

The strategic logic is not simply about adding molecules. Fresenius is trying to convert its biopharma arm from a business with a fixed portfolio into one that can repeatedly select, develop and commercialize products across a wider set of therapeutic areas. That is why the company links the deal to ambitions beyond 2030 and why it says it could potentially triple its portfolio. The option model lets it test that ambition without committing capital to all 37 candidates at once.

Execution risk remains substantial. Option rights are not products, and Fresenius has not said how many candidates it will ultimately select. Each programme will face development, regulatory and manufacturing decisions, and the company will make manufacturing choices candidate by candidate. The first two programmes, polatuzumab vedotin and teprotumumab, are complex products with established originator competition. The scale of the deal is clear. The eventual commercial return is not. Fresenius has bought a pipeline option, not a guaranteed portfolio, and the next decade will be judged on how many of those options become approved products.

Why It Matters

For patients and payers, the significance lies in what a larger biosimilar pipeline could do to competition in expensive biologic categories. Fresenius says the candidates address more than €370 billion in originator sales, a figure that reflects the scale of the branded market involved. More entrants can change price dynamics, but only after products clear development and regulatory review. The deal does not by itself bring any medicine to market. It expands the set of products Fresenius can choose to pursue.

For the industry, the agreement reinforces the role of China's contract research and manufacturing organisations in global drug development. WuXi Biologics is not selling assets. It is providing development capabilities, and Fresenius is retaining commercialization rights and product economics. That division of labour could become a template for companies that want pipeline breadth without building every capability in house. It also shows how a European healthcare group can use external development capacity to pursue a pipeline it might not build alone.

Fresenius's own scale gives the deal weight. The company reported €22.6 billion in 2025 revenue and more than 178,000 employees in over 60 countries. It is funding the agreement from operating cash flow and says no new financing is required. That matters for investors because it means the pipeline expansion is not accompanied by a new capital raise or a change to 2026 guidance. The third quarter results on 4 November 2026 will be the first market test of how the deal is being received.

Next Up

Fresenius reports third quarter results on 4 November 2026, two days after announcing the agreement. Investors will look for any change in tone on Biopharma spending, even though the company has said 2026 guidance and medium term targets are unchanged. Fresenius has also said it expects to raise long term Biopharma ambitions significantly, which sets up a contrast between stable near term numbers and a much larger long term pipeline story.

The first operational signals will come from the initial programmes. Fresenius is expected to begin with biosimilar versions of polatuzumab vedotin and teprotumumab, selecting candidates individually and deciding manufacturing on a product by product basis. The mAbxience network is one option, but Fresenius has not committed to a single manufacturing route. How quickly those first programmes move, and how many of the 37 options Fresenius exercises, will determine whether the largest announced biosimilars development deal becomes the largest realized one.